Immune checkpoint inhibitor‐related myocarditis in thymic epithelial tumors: Recent progress and perspectives

• DOI: 10.1002/mog2.31
• Publication Date: 2023-05-18T05:46:10Z
• Authors: Jianqiong Yin; Zhuoran Yao; Jing Pan; Lu Gan; Jianxin Xue
• Keywords: Cardiotoxicity; Thymic carcinoma

Abstract Thymic epithelial tumors (TETs) are rare anterior mediastinal malignancies originating in the thymus with poor outcomes, and standard platinum‐based chemotherapy shows limited efficacy for treating metastatic or recurrent disease. In this setting, further improved novel treatment strategies needed. Immune checkpoint inhibitors (ICIs) widely applied clinical practice cancer therapy early results of trials have brought notable objective responses lasting survival benefits to patients TETs. However, incidences immune‐related adverse events (irAEs), especially cardiac events, higher than those other tumor types. Myocarditis is a rapidly progressive life‐threatening irAE treated ICIs, thereby hindering utilization ICI TETs patients. Therefore, article aims review case series that evaluated ICIs provide an overview features fatal ICI‐related myocarditis Furthermore, we approach insights into immunobiology thymic focus on revealing mechanisms cardiotoxicity TETs, hoping several valuable maximizing therapeutic potential